Cormorant Private Healthcare Fund Iii Lp - Net Worth and Insider Trading
Cormorant Private Healthcare Fund Iii Lp Insider Ownership Reports
Based on ownership reports from SEC filings, as the reporting owner, Cormorant Private Healthcare Fund Iii Lp owns 16 companies in total, including Prometheus Biosciences Inc (RXDX) , Rain Oncology Inc (RAIN) , and Olema Pharmaceuticals inc (OLMA) among others .
Insider Ownership Summary of Cormorant Private Healthcare Fund Iii Lp
Ticker | Comapny | Transaction Date | Type of Owner |
---|---|---|---|
RXDX | Prometheus Biosciences Inc | 2021-03-11 | 10 percent owner |
RAIN | Rain Oncology Inc | 2021-04-22 | 10 percent owner |
OLMA | Olema Pharmaceuticals inc | 2020-11-18 | 10 percent owner |
2021-10-07 | 10 percent owner | ||
2021-06-24 | 10 percent owner | ||
2021-07-28 | 10 percent owner | ||
2023-04-20 | 10 percent owner | ||
2021-03-25 | 10 percent owner | ||
2021-06-23 | 10 percent owner | ||
2023-03-30 | 10 percent owner | ||
2021-06-16 | 10 percent owner | ||
2021-10-20 | 10 percent owner | ||
2021-09-14 | 10 percent owner | ||
2023-03-03 | 10 percent owner | ||
2023-10-02 | 10 percent owner | ||
2023-10-23 | 10 percent owner |
Cormorant Private Healthcare Fund Iii Lp Trading Performance
Cormorant Private Healthcare Fund Iii Lp Ownership Network
Cormorant Private Healthcare Fund Iii Lp Owned Company Details
What does Prometheus Biosciences Inc do?
Who are the key executives at Prometheus Biosciences Inc?
Cormorant Private Healthcare Fund Iii Lp is the 10 percent owner of Prometheus Biosciences Inc. Other key executives at Prometheus Biosciences Inc include Chief Financial Officer Keith W Marshall , director & President and CEO Mark C. Mckenna , and 10 percent owner Cedars Sinai Intellectual Property Co .
Prometheus Biosciences Inc (RXDX) Insider Trades Summary
Over the past 18 months, Cormorant Private Healthcare Fund Iii Lp made no insider transaction in Prometheus Biosciences Inc (RXDX). Other recent insider transactions involving Prometheus Biosciences Inc (RXDX) include a net sale of 10,000 shares made by Keith W Marshall ,
In summary, during the past 3 months, insiders sold 0 shares of Prometheus Biosciences Inc (RXDX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 10,000 shares of Prometheus Biosciences Inc (RXDX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 10,000 shares.
Prometheus Biosciences Inc (RXDX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Prometheus Biosciences Inc Insider Transactions
- Download to Excel(.xls)
What does Rain Oncology Inc do?
Who are the key executives at Rain Oncology Inc?
Cormorant Private Healthcare Fund Iii Lp is the 10 percent owner of Rain Oncology Inc. Other key executives at Rain Oncology Inc include 10 percent owner Kevin C Tang , Principal Fin. & Acc. Officer Josephine Bruce , and 10 percent owner Tang Capital Partners Lp .
Rain Oncology Inc (RAIN) Insider Trades Summary
Over the past 18 months, Cormorant Private Healthcare Fund Iii Lp made no insider transaction in Rain Oncology Inc (RAIN). Other recent insider transactions involving Rain Oncology Inc (RAIN) include a net purchase of 1,198,445 shares made by Kevin C Tang , and a net sale of 995,000 shares made by Boxer Capital, Llc .
In summary, during the past 3 months, insiders sold 0 shares of Rain Oncology Inc (RAIN) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,168,973 shares of Rain Oncology Inc (RAIN) were sold and 1,372,418 shares were bought by its insiders, resulting in a net purchase of 203,445 shares.
Rain Oncology Inc (RAIN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Rain Oncology Inc Insider Transactions
- Download to Excel(.xls)
What does Olema Pharmaceuticals inc do?
Who are the key executives at Olema Pharmaceuticals inc?
Cormorant Private Healthcare Fund Iii Lp is the 10 percent owner of Olema Pharmaceuticals inc. Other key executives at Olema Pharmaceuticals inc include 10 percent owner Paradigm Biocapital Advisors Lp , director & Chief Technology Officer Cyrus Harmon , and director & President and CEO Sean Bohen .
Olema Pharmaceuticals inc (OLMA) Insider Trades Summary
Over the past 18 months, Cormorant Private Healthcare Fund Iii Lp made no insider transaction in Olema Pharmaceuticals inc (OLMA). Other recent insider transactions involving Olema Pharmaceuticals inc (OLMA) include a net sale of 338,181 shares made by Cyrus Harmon , a net sale of 44,370 shares made by David C. Myles , and a net sale of 2,300,000 shares made by Paradigm Biocapital Advisors Lp .
In summary, during the past 3 months, insiders sold 2,430,000 shares of Olema Pharmaceuticals inc (OLMA) in total and bought 0 shares, with a net sale of 2,430,000 shares. During the past 18 months, 4,048,074 shares of Olema Pharmaceuticals inc (OLMA) were sold and 2,255,932 shares were bought by its insiders, resulting in a net sale of 1,792,142 shares.
Olema Pharmaceuticals inc (OLMA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Olema Pharmaceuticals inc Insider Transactions
- Download to Excel(.xls)
What does Pyxis Oncology Inc do?
Who are the key executives at Pyxis Oncology Inc?
Cormorant Private Healthcare Fund Iii Lp is the 10 percent owner of Pyxis Oncology Inc. Other key executives at Pyxis Oncology Inc include Chief Financial Officer Pamela Ann Connealy , Chief Accounting Officer Jitendra Wadhane , and director & Chief Executive Officer Lara Sullivan .
Pyxis Oncology Inc (PYXS) Insider Trades Summary
Over the past 18 months, Cormorant Private Healthcare Fund Iii Lp made no insider transaction in Pyxis Oncology Inc (PYXS). Other recent insider transactions involving Pyxis Oncology Inc (PYXS) include a net purchase of 31,426 shares made by Pamela Ann Connealy , a net purchase of 10,000 shares made by Jitendra Wadhane , and a net sale of 36,558 shares made by Lara Sullivan .
In summary, during the past 3 months, insiders sold 0 shares of Pyxis Oncology Inc (PYXS) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 36,558 shares of Pyxis Oncology Inc (PYXS) were sold and 41,426 shares were bought by its insiders, resulting in a net purchase of 4,868 shares.
Pyxis Oncology Inc (PYXS)'s detailed insider trading history can be found in Insider Trading Tracker table.
Pyxis Oncology Inc Insider Transactions
- Download to Excel(.xls)
What does Elevation Oncology Inc do?
Who are the key executives at Elevation Oncology Inc?
Cormorant Private Healthcare Fund Iii Lp is the 10 percent owner of Elevation Oncology Inc. Other key executives at Elevation Oncology Inc include CHIEF FINANCIAL OFFICER Tammy Furlong , 10 percent owner Robert J Adelman , and 10 percent owner Venbio Global Strategic Gp Iii, L.p. .
Elevation Oncology Inc (ELEV) Insider Trades Summary
In summary, during the past 3 months, insiders sold 0 shares of Elevation Oncology Inc (ELEV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Elevation Oncology Inc (ELEV) were sold and 0 shares were bought by its insiders, resulting in a net sale of 0 shares.
Elevation Oncology Inc (ELEV)'s detailed insider trading history can be found in Insider Trading Tracker table.
Elevation Oncology Inc Insider Transactions
- Download to Excel(.xls)
What does Icosavax Inc do?
Who are the key executives at Icosavax Inc?
Cormorant Private Healthcare Fund Iii Lp is the 10 percent owner of Icosavax Inc. Other key executives at Icosavax Inc include director & Chief Executive Officer Adam K. Simpson , Chief Medical Officer Niranjan Kanesa-thasan , and Chief Financial Officer Thomas Joseph Russo .
Icosavax Inc (ICVX) Insider Trades Summary
Over the past 18 months, Cormorant Private Healthcare Fund Iii Lp made no insider transaction in Icosavax Inc (ICVX). Other recent insider transactions involving Icosavax Inc (ICVX) include a net sale of 193,993 shares made by Adam K. Simpson , a net sale of 28,581 shares made by Cassia Cearley , and a net sale of 36,799 shares made by Douglas Holtzman .
In summary, during the past 3 months, insiders sold 0 shares of Icosavax Inc (ICVX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 292,829 shares of Icosavax Inc (ICVX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 292,829 shares.
Icosavax Inc (ICVX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Icosavax Inc Insider Transactions
- Download to Excel(.xls)
What does Immuneering Corp do?
Who are the key executives at Immuneering Corp?
Cormorant Private Healthcare Fund Iii Lp is the 10 percent owner of Immuneering Corp. Other key executives at Immuneering Corp include 10 percent owner Cormorant Asset Management, Lp , Vice President & Finance Mallory Morales , and Chief Business Officer Harold Eugene Brakewood .
Immuneering Corp (IMRX) Insider Trades Summary
Over the past 18 months, Cormorant Private Healthcare Fund Iii Lp made no insider transaction in Immuneering Corp (IMRX). Other recent insider transactions involving Immuneering Corp (IMRX) include a net sale of 1,309,091 shares made by Cormorant Asset Management, Lp , a net purchase of 100,000 shares made by Peter Feinberg , and a net purchase of 57,965 shares made by Ann E Berman .
In summary, during the past 3 months, insiders sold 0 shares of Immuneering Corp (IMRX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,309,091 shares of Immuneering Corp (IMRX) were sold and 197,083 shares were bought by its insiders, resulting in a net sale of 1,112,008 shares.
Immuneering Corp (IMRX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Immuneering Corp Insider Transactions
- Download to Excel(.xls)
What does Design Therapeutics Inc do?
Who are the key executives at Design Therapeutics Inc?
Cormorant Private Healthcare Fund Iii Lp is the 10 percent owner of Design Therapeutics Inc. Other key executives at Design Therapeutics Inc include director & President and CEO Joao Md Siffert , director & 10 percent owner Simeon George , and 10 percent owner Sr One Capital Fund I Aggregator Lp .
Design Therapeutics Inc (DSGN) Insider Trades Summary
Over the past 18 months, Cormorant Private Healthcare Fund Iii Lp made no insider transaction in Design Therapeutics Inc (DSGN). Other recent insider transactions involving Design Therapeutics Inc (DSGN) include a net purchase of 1,420,126 shares made by Arsani William , a net purchase of 26,965 shares made by John P. Schmid , and a net purchase of 21,000 shares made by Rodney W Lappe .
In summary, during the past 3 months, insiders sold 814,874 shares of Design Therapeutics Inc (DSGN) in total and bought 0 shares, with a net sale of 814,874 shares. During the past 18 months, 814,874 shares of Design Therapeutics Inc (DSGN) were sold and 2,296,265 shares were bought by its insiders, resulting in a net purchase of 1,481,391 shares.
Design Therapeutics Inc (DSGN)'s detailed insider trading history can be found in Insider Trading Tracker table.
Design Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does Monte Rosa Therapeutics Inc do?
Who are the key executives at Monte Rosa Therapeutics Inc?
Cormorant Private Healthcare Fund Iii Lp is the 10 percent owner of Monte Rosa Therapeutics Inc. Other key executives at Monte Rosa Therapeutics Inc include 10 percent owner Versant Venture Capital Vi, L.p. , Principal Accounting Officer Edmund Dunn , and General Counsel Philip Nickson .
Monte Rosa Therapeutics Inc (GLUE) Insider Trades Summary
Over the past 18 months, Cormorant Private Healthcare Fund Iii Lp made no insider transaction in Monte Rosa Therapeutics Inc (GLUE). Other recent insider transactions involving Monte Rosa Therapeutics Inc (GLUE) include a net sale of 2,817 shares made by Edmund Dunn , and a net sale of 567,213 shares made by Versant Venture Capital Vi, L.p. .
In summary, during the past 3 months, insiders sold 568,823 shares of Monte Rosa Therapeutics Inc (GLUE) in total and bought 0 shares, with a net sale of 568,823 shares. During the past 18 months, 570,030 shares of Monte Rosa Therapeutics Inc (GLUE) were sold and 0 shares were bought by its insiders, resulting in a net sale of 570,030 shares.
Monte Rosa Therapeutics Inc (GLUE)'s detailed insider trading history can be found in Insider Trading Tracker table.
Monte Rosa Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does Biomea Fusion Inc do?
Who are the key executives at Biomea Fusion Inc?
Cormorant Private Healthcare Fund Iii Lp is the 10 percent owner of Biomea Fusion Inc. Other key executives at Biomea Fusion Inc include Chief Financial Officer Franco Valle , Chief Medical Officer Juan Pablo Frias , and 10 percent owner A2a Pharmaceuticals, Inc. .
Biomea Fusion Inc (BMEA) Insider Trades Summary
Over the past 18 months, Cormorant Private Healthcare Fund Iii Lp made no insider transaction in Biomea Fusion Inc (BMEA). Other recent insider transactions involving Biomea Fusion Inc (BMEA) include a net sale of 1,000,000 shares made by A2a Pharmaceuticals, Inc. , a net purchase of 400,000 shares made by Cormorant Global Healthcare Master Fund, Lp , and a net purchase of 12,509 shares made by Franco Valle .
In summary, during the past 3 months, insiders sold 0 shares of Biomea Fusion Inc (BMEA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 1,000,000 shares of Biomea Fusion Inc (BMEA) were sold and 412,509 shares were bought by its insiders, resulting in a net sale of 587,491 shares.
Biomea Fusion Inc (BMEA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Biomea Fusion Inc Insider Transactions
- Download to Excel(.xls)
What does Verve Therapeutics Inc do?
Who are the key executives at Verve Therapeutics Inc?
Cormorant Private Healthcare Fund Iii Lp is the 10 percent owner of Verve Therapeutics Inc. Other key executives at Verve Therapeutics Inc include See Remarks Andrew D. Ashe , Chief Administrative Officer Joan Nickerson , and director & 10 percent owner Krishna Yeshwant .
Verve Therapeutics Inc (VERV) Insider Trades Summary
Over the past 18 months, Cormorant Private Healthcare Fund Iii Lp made no insider transaction in Verve Therapeutics Inc (VERV). Other recent insider transactions involving Verve Therapeutics Inc (VERV) include a net purchase of 1,800,000 shares made by Krishna Yeshwant , a net purchase of 76,000 shares made by Andrew D. Ashe , and a net sale of 1,514 shares made by Joan Nickerson .
In summary, during the past 3 months, insiders sold 0 shares of Verve Therapeutics Inc (VERV) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 2,068 shares of Verve Therapeutics Inc (VERV) were sold and 1,876,000 shares were bought by its insiders, resulting in a net purchase of 1,873,932 shares.
Verve Therapeutics Inc (VERV)'s detailed insider trading history can be found in Insider Trading Tracker table.
Verve Therapeutics Inc Insider Transactions
- Download to Excel(.xls)
What does Ventyx Biosciences Inc do?
Who are the key executives at Ventyx Biosciences Inc?
Cormorant Private Healthcare Fund Iii Lp is the 10 percent owner of Ventyx Biosciences Inc. Other key executives at Ventyx Biosciences Inc include director & Chief Executive Officer Raju Mohan , Chief Financial Officer Martin Auster , and Chief Scientific Officer John Nuss .
Ventyx Biosciences Inc (VTYX) Insider Trades Summary
Over the past 18 months, Cormorant Private Healthcare Fund Iii Lp made no insider transaction in Ventyx Biosciences Inc (VTYX). Other recent insider transactions involving Ventyx Biosciences Inc (VTYX) include a net sale of 773,232 shares made by Nsv Partners Iii Lp , a net sale of 773,232 shares made by Somu Subramaniam , and a net sale of 273,172 shares made by Raju Mohan .
In summary, during the past 3 months, insiders sold 0 shares of Ventyx Biosciences Inc (VTYX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 2,372,600 shares of Ventyx Biosciences Inc (VTYX) were sold and 0 shares were bought by its insiders, resulting in a net sale of 2,372,600 shares.
Ventyx Biosciences Inc (VTYX)'s detailed insider trading history can be found in Insider Trading Tracker table.
Ventyx Biosciences Inc Insider Transactions
- Download to Excel(.xls)
What does Tyra Biosciences Inc do?
Who are the key executives at Tyra Biosciences Inc?
Cormorant Private Healthcare Fund Iii Lp is the 10 percent owner of Tyra Biosciences Inc. Other key executives at Tyra Biosciences Inc include Chief Operating Officer Daniel Bensen , director & Chief Executive Officer Todd Harris , and 10 percent owner Mva Investors, Llc .
Tyra Biosciences Inc (TYRA) Insider Trades Summary
Over the past 18 months, Cormorant Private Healthcare Fund Iii Lp made no insider transaction in Tyra Biosciences Inc (TYRA). Other recent insider transactions involving Tyra Biosciences Inc (TYRA) include a net sale of 280,000 shares made by Daniel Bensen , and a net sale of 252,175 shares made by Todd Harris .
In summary, during the past 3 months, insiders sold 0 shares of Tyra Biosciences Inc (TYRA) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 532,175 shares of Tyra Biosciences Inc (TYRA) were sold and 0 shares were bought by its insiders, resulting in a net sale of 532,175 shares.
Tyra Biosciences Inc (TYRA)'s detailed insider trading history can be found in Insider Trading Tracker table.
Tyra Biosciences Inc Insider Transactions
- Download to Excel(.xls)
What does Ambrx Biopharma Inc do?
Who are the key executives at Ambrx Biopharma Inc?
Cormorant Private Healthcare Fund Iii Lp is the 10 percent owner of Ambrx Biopharma Inc. Other key executives at Ambrx Biopharma Inc include 10 percent owner Cormorant Asset Management, Lp , Chief Financial Officer Sonja Nelson , and director & President and CEO Daniel J. O'connor .
Ambrx Biopharma Inc (AMAM) Insider Trades Summary
Over the past 18 months, Cormorant Private Healthcare Fund Iii Lp made no insider transaction in Ambrx Biopharma Inc (AMAM). Other recent insider transactions involving Ambrx Biopharma Inc (AMAM) include a net purchase of 9,965,823 shares made by Cormorant Asset Management, Lp ,
In summary, during the past 3 months, insiders sold 0 shares of Ambrx Biopharma Inc (AMAM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 0 shares of Ambrx Biopharma Inc (AMAM) were sold and 9,965,823 shares were bought by its insiders, resulting in a net purchase of 9,965,823 shares.
Ambrx Biopharma Inc (AMAM)'s detailed insider trading history can be found in Insider Trading Tracker table.
Ambrx Biopharma Inc Insider Transactions
- Download to Excel(.xls)
What does MoonLake Immunotherapeutics do?
Who are the key executives at MoonLake Immunotherapeutics?
Cormorant Private Healthcare Fund Iii Lp is the 10 percent owner of MoonLake Immunotherapeutics. Other key executives at MoonLake Immunotherapeutics include director & Chief Executive Officer Santos Da Silva Jorge , Chief Scientific Officer Kristian Reich , and Chief Financial Officer Matthias Bodenstedt .
MoonLake Immunotherapeutics (MLTX) Insider Trades Summary
Over the past 18 months, Cormorant Private Healthcare Fund Iii Lp made no insider transaction in MoonLake Immunotherapeutics (MLTX). Other recent insider transactions involving MoonLake Immunotherapeutics (MLTX) include a net purchase of 1,629,151 shares made by Bihua Chen , a net sale of 200,000 shares made by Kristian Reich , and a net sale of 184,740 shares made by Santos Da Silva Jorge .
In summary, during the past 3 months, insiders sold 0 shares of MoonLake Immunotherapeutics (MLTX) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 484,740 shares of MoonLake Immunotherapeutics (MLTX) were sold and 1,629,151 shares were bought by its insiders, resulting in a net purchase of 1,144,411 shares.
MoonLake Immunotherapeutics (MLTX)'s detailed insider trading history can be found in Insider Trading Tracker table.
MoonLake Immunotherapeutics Insider Transactions
- Download to Excel(.xls)
What does Ambrx Biopharma Inc do?
Who are the key executives at Ambrx Biopharma Inc?
Cormorant Private Healthcare Fund Iii Lp is the 10 percent owner of Ambrx Biopharma Inc. Other key executives at Ambrx Biopharma Inc include Chief Financial Officer Sonja Nelson , director & President and CEO Daniel J. O'connor , and 10 percent owner Cormorant Asset Management, Lp .
Ambrx Biopharma Inc (AMAM) Insider Trades Summary
Over the past 18 months, Cormorant Private Healthcare Fund Iii Lp made no insider transaction in Ambrx Biopharma Inc (AMAM). Other recent insider transactions involving Ambrx Biopharma Inc (AMAM) include a net purchase of 1,307,311 shares made by Cormorant Asset Management, Lp , a net sale of 50,012 shares made by Daniel J. O'connor , and a net sale of 12,778 shares made by Sonja Nelson .
In summary, during the past 3 months, insiders sold 0 shares of Ambrx Biopharma Inc (AMAM) in total and bought 0 shares, with a net sale of 0 shares. During the past 18 months, 62,790 shares of Ambrx Biopharma Inc (AMAM) were sold and 1,307,311 shares were bought by its insiders, resulting in a net purchase of 1,244,521 shares.
Ambrx Biopharma Inc (AMAM)'s detailed insider trading history can be found in Insider Trading Tracker table.
Ambrx Biopharma Inc Insider Transactions
- Download to Excel(.xls)
Cormorant Private Healthcare Fund Iii Lp Mailing Address
Above is the net worth, insider trading, and ownership report for Cormorant Private Healthcare Fund Iii Lp. You might contact Cormorant Private Healthcare Fund Iii Lp via mailing address: 200 Clarendon Street, 52nd Floor, Boston Ma 02116.
Discussions on Cormorant Private Healthcare Fund Iii Lp
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey